AIM-HIGH Trial

Study / Research

A large cardiovascular outcomes trial that showed no cardiovascular benefits from niacin therapy.

Mentioned in 2 videos

Videos Mentioning AIM-HIGH Trial

#23–Tom Dayspring Part IV of V: statins, Zetia, PCSK9 inhibitors, niacin, cholesterol & the brain

#23–Tom Dayspring Part IV of V: statins, Zetia, PCSK9 inhibitors, niacin, cholesterol & the brain

Peter Attia MD

A large randomized, prospective, blinded trial designed to test the effect of adding niacin to statin therapy to raise HDL-C in patients with optimized LDL-C. It failed to show additional cardiovascular event reduction despite lowering ApoB.

210 - Lp(a) and its impact on heart disease | Benoît Arsenault, Ph.D.& Peter Attia, M.D.

210 - Lp(a) and its impact on heart disease | Benoît Arsenault, Ph.D.& Peter Attia, M.D.

Peter Attia MD

A large cardiovascular outcomes trial that showed no cardiovascular benefits from niacin therapy.